Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Medtronic
Cerilliant
Johnson and Johnson
Teva
Mallinckrodt
UBS
Cantor Fitzgerald
Express Scripts

Generated: February 24, 2018

DrugPatentWatch Database Preview

LEXISCAN Drug Profile

« Back to Dashboard

Which patents cover Lexiscan, and when can generic versions of Lexiscan launch?

Lexiscan is a drug marketed by Astellas and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-four patent family members in twenty-six countries.

The generic ingredient in LEXISCAN is regadenoson. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the regadenoson profile page.
Summary for LEXISCAN
International Patents:84
US Patents:17
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 34
Clinical Trials: 42
Patent Applications: 54
Drug Prices:see details
DailyMed Link:LEXISCAN at DailyMed
Drug patent expirations by year for LEXISCAN
Pharmacology for LEXISCAN

US Patents and Regulatory Information for LEXISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LEXISCAN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 0.08 mg/mL, 5 mL vial ➤ Subscribe 4/10/2012

Non-Orange Book US Patents for LEXISCAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,671,192 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
8,524,883 Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide ➤ Try a Free Trial
8,278,435 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
8,071,566 Methods of coronary imaging ➤ Try a Free Trial
8,906,878 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
9,163,057 Methods of myocardial perfusion imaging ➤ Try a Free Trial
7,956,179 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
8,569,260 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
7,732,595 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
8,268,988 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for LEXISCAN

Supplementary Protection Certificates for LEXISCAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2/2011 Austria ➤ Try a Free Trial PRODUCT NAME: REGADENOSON UND DESSEN SALZE
C0004 France ➤ Try a Free Trial PRODUCT NAME: REGADENOSON ET SES SELS; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2011 Austria ➤ Try a Free Trial PRODUCT NAME: REGADENOSON UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2011 00005 Denmark ➤ Try a Free Trial PRODUCT NAME: REGADENOSON OG SALTE DERAF
2 Finland ➤ Try a Free Trial
C/GB11/005 United Kingdom ➤ Try a Free Trial PRODUCT NAME: REGADENOSON; REGISTERED: UK EU/1/10/643/001 20100906
90003-2.L Sweden ➤ Try a Free Trial PRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
C004/2011 Ireland ➤ Try a Free Trial SPC004/2011: 20110719, EXPIRES: 20250620
00477 Netherlands ➤ Try a Free Trial PRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
785 Luxembourg ➤ Try a Free Trial 91785, EXPIRES: 20250621
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
QuintilesIMS
Express Scripts
AstraZeneca
Healthtrust
Argus Health
Federal Trade Commission
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot